1st Quarter - Report

DUTKO WORLDWIDE, LLC for GLAXOSMITHKLINE

Firm
Client
Income
$40,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

Monitor federal legislation related to patent reform and other health care issues and advise client as it affects them, including Patent Reform Act of 2009 (H.R.1260/ S.515/S.610), Budget resolution FY2010 (bill number has not yet been assigned), Pathway for Biosimilars Act (H.R. 1548) & American Recovery and Reinvestment Act of 2009 (HR1) as it relates to comparative effectiveness research funding. Health Care Reform Legislation (to date no specific bills have been introduced). Pharmaceutical import safety legislation.

LobbyistCovered position, as disclosed
JUDITH LEMONS —
CECIL SWAMIDOSS —
DARREN WILLCOX —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1260 (111th), S. 610 (111th), H.R. 1548 (111th), H.R. 1 (111th), S. 515 (111th)

Health Issues HCR

Monitor federal legislation related to patent reform and other health care issues and advise client as it affects them, including Patent Reform Act of 2009 (H.R.1260/ S.515/S.610), Budget resolution FY2010 (bill number has not yet been assigned), Pathway for Biosimilars Act (H.R. 1548) & American Recovery and Reinvestment Act of 2009 (HR1) as it relates to comparative effectiveness research funding. Health Care Reform Legislation (to date no specific bills have been introduced). Pharmaceutical import safety legislation.

LobbyistCovered position, as disclosed
JUDITH LEMONS —
CECIL SWAMIDOSS —
DARREN WILLCOX —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 515 (111th), H.R. 1260 (111th), H.R. 1 (111th), S. 610 (111th), H.R. 1548 (111th)

Medicare/Medicaid MMM

Monitor federal legislation related to medicare and other health care issues and advise client as it affects them, including Patent Reform Act of 2009 (H.R.1260/ S.515/S.610), Budget resolution FY2010 (bill number has not yet been assigned), Pathway for Biosimilars Act (H.R. 1548) & American Recovery and Reinvestment Act of 2009 (HR1) as it relates to comparative effectiveness research funding. Health Care Reform Legislation (to date no specific bills have been introduced). Pharmaceutical import safety legislation.

LobbyistCovered position, as disclosed
JUDITH LEMONS —
DARREN WILLCOX —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1 (111th), H.R. 1260 (111th), S. 610 (111th), H.R. 1548 (111th), S. 515 (111th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.